| Original language | English (US) |
|---|---|
| Pages (from-to) | 319-340 |
| Number of pages | 22 |
| Journal | Neurologic clinics |
| Volume | 42 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 2024 |
Keywords
- COVID-19
- Disease-modifying therapy
- Multiple sclerosis
- Registries
- Telemedicine
- Vaccination
ASJC Scopus subject areas
- Clinical Neurology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Neurologic clinics, Vol. 42, No. 1, 02.2024, p. 319-340.
Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Era of COVID-19 in Multiple Sclerosis Care
AU - Krett, Jonathan D.
AU - Salter, Amber
AU - Newsome, Scott D.
N1 - Funding Information: J.D. Krett: receives fellowship funding (paid directly to institution) provided by the National Multiple Sclerosis Society and a University of Calgary Medical Group Helios Advanced Training Award. A. Salter: receives research funding (paid directly to institution) from Multiple Sclerosis Canada , National Multiple Sclerosis Society , Consortium of Multiple Sclerosis Centers and the Department of Defense Congressionally Directed Medical Research Program and is a member of the editorial board for Neurology. She serves as a consultant for Gryphon Bio, LLC. She is a member of the Data and Safety Monitoring Board for Premature Infants Receiving Milking or Delayed Cord Clamping (PREMOD2), Central Vein Sign: A Diagnostic Biomarker in Multiple Sclerosis (CAVS-MS), and Methotrexate treatment of Arthritis caused by Chikungunya virus (MARCH). She is supported (in part) by a Biostatistics/Informatics Junior Faculty Award ( BI-2105-37656 ) from the National Multiple Sclerosis Society, United States . She holds the Kenney Marie Dixon-Pickens Distinguished Professorship in Multiple Sclerosis Research. S.D. Newsome received consultant fees for scientific advisory boards from Biogen, Genentech, Bristol Myers Squibb, EMD Serono, Greenwich Biosciences, Horizon Therapeutics, Novartis, TG Therapeutics; study lead PI for a Roche clinical trial program; advisor to Autobahn; received research funding (paid directly to institution) from Biogen, United States , Lundbeck, Denmark , Roche, Switzerland , Genentech, United States , National MS Society, United States , The Stiff Person Syndrome Research Foundation , Department of Defense, and Patient Centered Outcomes Research Institute.
PY - 2024/2
Y1 - 2024/2
KW - COVID-19
KW - Disease-modifying therapy
KW - Multiple sclerosis
KW - Registries
KW - Telemedicine
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=85167829284&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85167829284&partnerID=8YFLogxK
U2 - 10.1016/j.ncl.2023.06.006
DO - 10.1016/j.ncl.2023.06.006
M3 - Review article
C2 - 37980121
AN - SCOPUS:85167829284
SN - 0733-8619
VL - 42
SP - 319
EP - 340
JO - Neurologic clinics
JF - Neurologic clinics
IS - 1
ER -